Swiss Medtech Startup Rovica Raises $ 2.5m for emergency neurosurgical devices

Rovica NeurimizingBurn-based Medtech startup, Extremely Neurosurgery Extremely Drainage (EVD) has collected $ 2.5 million in a financing to accelerate the development of the Bedside Navigation system in Rovica for catheters.

The round was led by M2 Care with the participation of Kickfand, Value Maker and several other business angels.

Martin HlavicaRovika’s CEO and co-founder, says: “These funds marked as an important milestone for Rovika. Our investors’ confidence strengthens our ability to move forward to the development of Sonov and to make this solution more close to the necessary patients.“

The neurosurgeon Martin Hlavica and Thomas Romberg are invented in 2023, innovating to solve emergency treatment for patients to increase brain pressure as life-threatening brain stress.

According to the agency, one of the common methods of this national is to set up an EVD to relieve dangerous higher brain stress. Today, it is often freehanded in beds – fast but useless – or with navigation systems in the operating room, which delays emergency care. In speed and accuracy, this trade can worse the patient’s results.

The goal of the Rovika’s gold system is to solve this challenge with integrated censors that provide real-time visualization for the guided catheter insert in the bed. The technology is reported to be able to enable the brain ventricles, to reduce CT scans, improve protection and improve outcomes and reduce costs.

Florence ThouxM2 Care President commented: “M2 Care Hand-on Efficiently combines investment capabilities to make primary health-centric initiatives risky for a preparation series. Rovika reflects this approach: a strong team and a technology that addresses a clear clinical need with an emergency neurosurgery. We are proud to actively support the agency in this subsequent stage of developmentThe “

Rovica addresses a critical challenge in emergency neurosurgery: to set the safe and quick space of life -saving EVD catheters to relieve increased intracranial stress, for example after serious trauma or intracranial bleeding.

With this approach, the agency itself is located in the market environment, which is expected to grow between 4.5% to 14.2% in the coming years – according to the statistics given by Rovica.

To further strengthen its development, Rovika has appointed Managing Director Kirsten Lau to his board of directors at M2 Care. His skills in the Medtech Strategies and the company will support the company in advance of the clinical adoption.

Light Connected: “By joining the Rovica board, I am actively expected to actively support the team to translate a powerful clinical need into an effective medtech solution. Emergency Neurosurgical Care, the source of the project, combined with the complement of the founders, reflects the innovation that has been set up to accelerate M2 CareThe “